Aligos Secures $25M Upfront in China HBV Drug Deal, Extends Cash Runway
summarizeSummary
Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. for its lead chronic Hepatitis B Virus (HBV) drug candidate, pevifoscorvir sodium, in Greater China. The deal includes a significant $25 million upfront payment, up to $420 million in potential clinical, regulatory, and sales milestones, and tiered high single-digit royalties on net sales. This substantial upfront payment is highly material for Aligos, which has a market capitalization of approximately $46 million, and directly addresses the 'going concern' warning from its last 10-K by extending its cash runway from Q3 2026 into Q4 2026. This partnership, following the recent FDA Fast Track designation for pevifoscorvir sodium, strategically positions the drug for development and commercialization in a key market with a high HBV prevalence, leveraging Amoytop's leadership in the region. Investors will now watch for the conditional approval from Amoytop's shareholders and further progress in the Phase 2 B-SUPREME study, with interim analysis expected in H2 2026.
في وقت هذا الإعلان، كان ALGS يتداول عند ٨٫٥٠ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٤٥٫٩ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٤٫١٣ US$ و١٣٫٦٩ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٩ من 10. المصدر: GlobeNewswire.